Early access
Sign in
Taking people in United KingdomPhase 3

Eloralintide for knee osteoarthritis pain in adults who are overweight or have obesity

Tests eloralintide against placebo in adults with painful knee osteoarthritis and excess weight.

Key facts

Who runs it
Eli Lilly and Company
Where
Bristol, Glasgow, London, Newcastle, Penzance, Rotherham, Sheffield, and York, United KingdomSee the 8 sitesAlso in 12 other countries, 138 sites
Trial code
Registry title
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Status
Recruiting
Phase
Phase 3
People taking part
900 people, planned
Started
9 Feb 2026
Expected to end
May 2028
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Eloralintide
  • Placebo
Record updated
4 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with knee osteoarthritis pain who also have overweight or obesity (BMI of 27 kg/m² or higher) and have not lost weight through diet.

Age
18 years or older
Sex
All sexes can join
Disease stage
Osteoarthritis of the knee with pain, and at least one of: over 50 years old, morning knee stiffness lasting about 30 minutes, or a crackling or grinding feeling in the knee.
Earlier treatment
Must have tried at least once to lose weight through diet without success. Must not have taken weight-loss medications or alternative remedies within 90 days of screening.
Biomarker or test result
BMI of 27 kg/m² or higher at screening; stable body weight (less than 5% change) for 90 days before screening.

Main reasons for not taking part

  • Any type of diabetes (type 1, type 2 or other)
  • Surgery or endoscopic or device-based treatment for obesity (some exceptions if long ago)
  • Active knee infection
  • Heart attack, stroke, coronary artery revascularization, unstable angina or hospitalization for heart failure within 90 days before screening
  • Class IV congestive heart failure (New York Heart Association)

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Have a body mass index (BMI) of 27 kilograms per square meter (kg/m²) or higher at screening
  • Have a stable body weight (less than 5% body weight change) for 90 days prior to screening
  • Have tried at least once to lose weight through diet but were unsuccessful
  • Have osteoarthritis of the knee and at least one of the following conditions:; Be over 50 years old; Have morning knee stiffness that lasts about 30 minutes; Have a crackling or grinding sound or feeling in the knee

Who cannot take part

  • Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed greater than 1 year before screening)
  • Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
  • Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure
  • Have taken medications or alternative remedies intended for weight loss within 90 days of screening
  • Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
  • Have an active knee infection
  • Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure

Where in United Kingdom

Also in 12 other countries, 138 sites

  • Velocity Clinical Research, BristolBristol, United KingdomContact: Kirsten Peacey (principal investigator)Taking people
  • FutureMeds Glasgow - CPS ResearchGlasgow, United KingdomContact: Kristen Laing (principal investigator)Taking people
  • FutureMeds - LondonLondon, United KingdomContact: Pembe Ozunlu (principal investigator)Taking people
  • Futuremeds-NewcastleNewcastle, United KingdomContact: William Aspinall (principal investigator)Taking people
  • Atlantic MedicalPenzance, United KingdomContact: Alex Dewdney (principal investigator)Taking people
  • Woodstock Bower SurgeryRotherham, United KingdomContact: Shahbaz Ali (principal investigator)Taking people
  • Panthera Biopartners - SheffieldSheffield, United KingdomContact: Hannah Collins (principal investigator)Taking people
  • Panthera Clinic - YorkYork, United KingdomContact: Mahadev Ramjee (principal investigator)Taking people

About the trial

What the trial wants to find out

The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.

The 4 groups in the trial

  • Eloralintide (YOA1)Treatment being tested

    Participants will receive eloralintide subcutaneously (SC)

    Treatment: Eloralintide

  • Placebo (YOA1)Placebo, for comparison

    Participants will receive placebo SC

    Treatment: Placebo

  • Eloralintide (YOA2)Treatment being tested

    Participants will receive eloralintide SC

    Treatment: Eloralintide

  • Placebo (YOA2)Placebo, for comparison

    Participants will receive placebo SC

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4)
Plain-language title
Eloralintide for knee osteoarthritis pain in adults who are overweight or have obesityGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
4 November 2026